Abstract
Purpose
To identify potential genetic markers in treated stage II–III colorectal cancer patients and predict 3-year tumor relapse using statistical models based on important clinical factors and significant genetic markers.
Methods
Gene expression profiling by cDNA-mediated Annealing, Selection, extension and Ligation assay was performed in a prospectively collected 95 stage II–III colorectal cancer patients with Fluorouracil-based adjuvant chemotherapy. We studied the gene expression level of 502 genes for patients with different outcomes. The prognostic effect of genetic signature was evaluated in multivariate analysis. We further integrated the genetic signature to clinical Classification of Malignant Tumors (TNM) staging system for predicting of 3-year tumor relapse.
Results
An 8-gene signature was identified to well discriminate patients with different treatment outcomes. An integrated risk factor, which including 8-gene signature and TNM staging has been developed. ROC curve revealed that our integrated risk factor was better than genetic signature or current sixth edition TNM staging system alone.
Conclusions
Our 8-gene signature was promising in predicting 3-year disease-free survival rate for locally advanced colorectal cancer. The integrated risk factor, which combining genetic signature with clinical TNM staging system may further improve the outcome prediction.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66
Greene FL, Page D, Fleming ID et al (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York
Compton C, Greene F (2004) The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54:295–308
O’Connell J, Maggard M, Ko C (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425
Bibikova M, Talantov D, Chudin E, Yeakley J, Chen J, Doucet D et al (2004) Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165:1799–1807
Haller A, Kanakapalli D, Walter R, Alhasan S, Eliason J, Everson R (2006) Transcriptional profiling of degraded RNA in cryopreserved and fixed tissue samples obtained at autopsy. BMC Clin Pathol 6:9
Illumina: Gene Expression on Sentrix Arrays: DASL Assay System Manual. Doc # 11175105 edn: Illumina Inc 2004
Fan J, Yeakley J, Bibikova M, Chudin E, Wickham E, Chen J et al (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14:878–885
Illumina. BeadStudio User Guide. vol Doc # 11179632 Rev A San Diego: Illumina Inc 2004
Bolstad B, Irizarry R, Astrand M, Speed T (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185–193
Dunning M, Smith M, Ritchie M, Tavare S (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23:2183–2184
Chen H, Yu S, Chen C, Chang G, Chen C, Yuan A et al (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11–20
Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG (2005) Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 97:1705–1706, author reply 6–7
Alvarado M, Jensen E, Yeatman T (2006) The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control 13:27–31
Barrier A, Boelle P, Roser F, Gregg J, Tse C, Brault D et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24:4685–4691
Bustin S, Dorudi S (2004) Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer. Expert Rev Mol Diagn 4:599–607
Cardoso J, Boer J, Morreau H, Fodde R (2007) Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 1775:103–137
Wang Y, Jatkoe T, Zhang Y, Mutch M, Talantov D, Jiang J et al (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 22:1564–1571
Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S et al (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 105:19432–19437
Watanabe T, Kobunai T, Toda E, Kanazawa T, Kazama Y, Tanaka J et al (2007) Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res 13:415–420
Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R et al (2005) Gene-expression profiling predicts recurrence in Dukes’ C colorectal cancer. Gastroenterology 129:874–884
Eschrich S (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526–3535
Wiese AH, Auer J, Lassmann S, Nahrig J, Rosenberg R, Hofler H et al (2007) Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 31:282–295
Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedel F et al (2009) Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 29:67–74
Theret N, Musso O, Campion JP, Turlin B, Loreal O, L’Helgoualc’h A et al (1997) Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer 74:426–432
Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD (2005) Insulin-like growth factor polymorphisms and colorectal cancer risk. Canc Epidemiol Biomarkers Prev 14:1204–1211
Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062
Sirvent A, Benistant C, Pannequin J, Veracini L, Simon V, Bourgaux JF et al (2010) Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene 29:1303–1315
Ingley E (2008) Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784:56–65
Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L et al (2007) Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 67:7907–7916
Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, Gehan E et al (2004) Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 64:7346–7354
Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK et al (2006) BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem 281:14654–14662
Beischlag TV, Perdew GH (2005) ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem 280:21607–21611
Lofstedt T, Fredlund E, Noguera R, Navarro S, Holmquist-Mengelbier L, Beckman S et al (2009) HIF-1alpha induces MXI1 by alternate promoter usage in human neuroblastoma cells. Exp Cell Res 315:1924–1936
Taj MM, Tawil RJ, Engstrom LD, Zeng Z, Hwang C, Sanda MG et al (2001) Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. Prostate 47:194–204
Camilleri-Broet S, Cremer I, Marmey B, Comperat E, Viguie F, Audouin J et al (2007) TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 26:142–147
Tomasetto C, Regnier CH, Rio MC (1998) TRAF-4 expression in breast carcinomas. Am J Pathol 153:2007–2008
Dejmek J, Leandersson K, Manjer J, Bjartell A, Emdin SO, Vogel WF et al (2005) Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res 11:520–528
Acknowledgements
The authors are grateful for the assistance of W. Huang, G. Yan in preparing and collection of clinical data. This work was supported by the grants from Science and Technology Commission of Shanghai Municipality program KWZD0703, National Key Project for Basic Research (2004CB518605) and Chinese National Natural Science Fund for Distinguished Young Scholars (30625019).
Conflict of interest statement
The author(s) indicated no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Junjie Peng and Zhimin Wang contributed equally to this article.
Rights and permissions
About this article
Cite this article
Peng, J., Wang, Z., Chen, W. et al. Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer. Int J Colorectal Dis 25, 1277–1285 (2010). https://doi.org/10.1007/s00384-010-1043-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-010-1043-1